Wyeth and closely-held Trubion Pharmaceuticals Inc. have agreed to develop and market antibody-like drugs, the Wall Street Journal reported on Tuesday. In the deal, Wyeth would make an upfront payment to Trubion of $40 million, the newspaper reported, citing the companies. It said that if certain milestones are met the arrangement could be worth as much as $800 million. The Journal also reported that Wyeth agreed to take an equity stake in Trubion if the company goes public. Representatives at Trubion and Wyeth could not immediately be reached for comment.
